BA Cambridge 1976
BM, BCh Oxford 1980
MRCP (UK) 1983
FRC Path 1999
Fellow of the Academy of Medical Sciences (2003)
ScD Cambridge 2006
Fellow of the Royal Society 2019
During my medical training I carried out studies on lung function, genetic polymorphisms, endocrine function and demography in high altitude populations in Nepal. In my PhD I established a model of respiratory syncytial (RS) virus infection in the mouse, and studied the T lymphocyte response to RS virus first in the mouse and then in the human.
Since 1987 I have studied the virology and immunology of persistent virus infections, in particular infection with the human T-cell leukaemia virus (HTLV-I) - see https://doi.org/10.26320/SCIENTIA225
. Our aim is to produce a comprehensive, coherent, qualitative and quantitative understanding of the persistence of HTLV-I and the immune response to HTLV-I, and an explanation of why certain individuals infected with HTLV-I develop fatal or disabling diseases while the majority remain asymptomatic. We use a broad range of techniques in molecular and cellular immunology, viral and host genetics, cell biology, DNA expression microarrays, proteomics and mathematics.
Bangham CRM, 2023, HTLV-1 persistence and the oncogenesis of adult T cell leukemia/lymphoma., Blood
et al., 2023, A frequent PLC gamma 1 mutation in adult T-cell leukemia/lymphoma determines functional properties of the malignant cells, Biochimica Et Biophysica Acta-molecular Basis of Disease, Vol:1869, ISSN:0925-4439
et al., 2023, The transcriptome of HTLV-1-infected primary cells following reactivation reveals changes to host gene expression central to the proviral life cycle
et al., 2022, Dynamics and consequences of the HTLV-1 proviral plus-strand burst, Plos Pathogens, Vol:18, ISSN:1553-7366
et al., 2022, HDAC inhibitors Panobinostat and Romidepsin enhance tax transcription in HTLV-1-infected cell lines and freshly isolated patients' T-cells, Frontiers in Immunology, Vol:13, ISSN:1664-3224